The transaction brings larsucosterol, an investigational treatment for alcoholic hepatitis, under Bausch Health’s portfolio ...

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...

The FDA’s top vaccine and gene therapy official resigned amid heightened scrutiny over recent drug approval decisions and ...

Zura Bio’s CEO and director Robert Lisicki discusses how his path to leadership taught him the importance of building a team ...

The survey reveals how financial anxiety has become an everyday occurrence affecting everyday health through stress, ...

GSK sponsors the 2025 National Senior Games to raise awareness about RSV risks and prevention for older adults through ...

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and ...

Following a complete response letter rejecting accelerated approval for RP1 in advanced melanoma, IGNYTE trial investigators are urging the FDA to reevaluate the therapy’s robust survival data, just ...

Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

The restructuring includes the elimination of certain roles and a reduction in the company’s global real estate footprint.

The extended review for Elinzanetant is supported by data from the Phase III OASIS 1, 2, and 3 trials, which supported the ...